- Home
- GMAB vs LAD Comparison
GMAB vs LAD Comparison
Compare GMAB & LAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- LAD
- Stock Information
- Founded
- GMAB 1999
- LAD 1946
- Country
- GMAB Denmark
- LAD United States
- Employees
- GMAB N/A
- LAD N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- LAD Retail-Auto Dealers and Gas Stations
- Sector
- GMAB Health Care
- LAD Consumer Discretionary
- Exchange
- GMAB Nasdaq
- LAD Nasdaq
- Market Cap
- GMAB 12.1B
- LAD 10.2B
- IPO Year
- GMAB N/A
- LAD 1996
- Fundamental
- Price
- GMAB $24.14
- LAD $305.21
- Analyst Decision
- GMAB Buy
- LAD Strong Buy
- Analyst Count
- GMAB 9
- LAD 14
- Target Price
- GMAB $40.71
- LAD $373.71
- AVG Volume (30 Days)
- GMAB 1.2M
- LAD 365.4K
- Earning Date
- GMAB 05-01-2025
- LAD 04-23-2025
- Dividend Yield
- GMAB N/A
- LAD 0.70%
- EPS Growth
- GMAB 83.82
- LAD N/A
- EPS
- GMAB 16.85
- LAD 29.65
- Revenue
- GMAB $2,988,286,182.00
- LAD $36,188,200,000.00
- Revenue This Year
- GMAB $19.59
- LAD $8.24
- Revenue Next Year
- GMAB $14.50
- LAD $7.72
- P/E Ratio
- GMAB $14.08
- LAD $10.29
- Revenue Growth
- GMAB 30.67
- LAD 16.58
- 52 Week Low
- GMAB $18.64
- LAD $243.00
- 52 Week High
- GMAB $31.88
- LAD $405.68
- Technical
- Relative Strength Index (RSI)
- GMAB 71.05
- LAD 21.28
- Support Level
- GMAB $23.63
- LAD $310.11
- Resistance Level
- GMAB $24.11
- LAD $319.80
- Average True Range (ATR)
- GMAB 0.37
- LAD 10.25
- MACD
- GMAB 0.22
- LAD -5.81
- Stochastic Oscillator
- GMAB 93.88
- LAD 8.80
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About LAD Lithia Motors Inc.
Lithia Motors is a retailer of new and used vehicles and related services. The company offers over 50 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2023 was $31 billion and we see over $50 billion possible in a few years. The US was 90% of 2023 revenue and the UK second at 6%, the latter should rise to around 20% with the 2024 Pendragon acquisition. In 2023, new-car sales were about 49% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.